Development and validation of an ELISA method for the plasma from non-small-cell lung cancer patients

Citation Report

#	Article	IF	Citations
1	Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. Critical Reviews in Analytical Chemistry, 2018, 48, 317-329.	1.8	14
2	An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2018, 40, 716-724.	1.0	24
3	Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations. Therapeutic Drug Monitoring, 2018, 40, 596-601.	1.0	15
4	Development of a simple, rapid and high-throughput fluorescence polarization immunoassay for glycocholic acid in human urine. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 431-437.	1.4	12
5	Development and validation of indirect and generic immunoassays to quantify free and total evolocumab in rat serum. Bioanalysis, 2019, 11, 679-687.	0.6	0
6	An efficient and quantitative assay for epitope-tagged therapeutic protein development with a capillary western system. Bioanalysis, 2019, 11, 471-483.	0.6	3
7	Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers, 2019, 11, 1784.	1.7	28
8	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 128-134.	1.4	47
9	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
10	Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion. Analytical Methods, 2020, 12, 54-62.	1.3	11
11	The impact of body composition parameters on severe toxicity of nivolumab. European Journal of Cancer, 2020, 124, 170-177.	1.3	32
12	Validation of a Double-Sandwich Enzyme-Linked Immunoassay for Pharmacokinetic Study of an rh-aFGF Hydrogel in Rat Skin and Serum. Frontiers in Pharmacology, 2020, 11, 700.	1.6	2
13	Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics, 2020, 12, 595.	2.0	7
14	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 2020, 12, 473.	1.7	72
15	Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta, 2021, 224, 121889.	2.9	18
16	Phase-specific cancer-immune model considering acquired resistance to therapeutic agents. Applied Mathematics and Computation, 2021, 391, 125555.	1.4	0
17	Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question. Clinical and Translational Oncology, 2021, 23, 1511-1519.	1.2	2
18	Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. Biomedicines, 2021, 9, 621.	1.4	6

#	Article	IF	Citations
19	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals, 2021, 14, 796.	1.7	13
20	Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients. European Journal of Clinical Pharmacology, 2022, 78, 77-87.	0.8	6
21	Optimization of polydopamine imprinted polymer for label free sensitive potentiometric determination of proteins: Application to recombinant human erythropoietin sensing in different matrices. Microchemical Journal, 2021, 167, 106333.	2.3	12
22	A Simple Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Related Substances, Assay of Cabozantinib and Nivolumab and its Application to Dissolution Studies. , 2021, 83, .		1
23	Quantification of the anti-murine PD-1 monoclonal antibody RMP1-14 in BALB/c mouse plasma by liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study. Analytical and Bioanalytical Chemistry, 2020, 412, 739-752.	1.9	0
24	Construction of Quantitative Analysis Workflow for Determination of Serum Concentrations of Monoclonal Antibody Drugs Aiming to Promote Therapeutic Drug Monitoring in Clinical Practice. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 161-166.	0.1	0
25	Rituximab exposureâ€response in triweekly Râ€CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. Clinical and Translational Science, 2022, 15, 680-690.	1.5	3
26	Reduced Graphene Oxide Based Electronic Sensors for Rapid and Label-Free Detection of CEA and CYFRA 21-1. IEEE Sensors Journal, 2022, 22, 1138-1145.	2.4	4
27	Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics, 2022, 14, 692.	2.0	6
28	Properties and Applications of Graphene and Its Derivatives in Biosensors for Cancer Detection: A Comprehensive Review. Biosensors, 2022, 12, 269.	2.3	37
29	Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab. Microchemical Journal, 2022, 182, 107896.	2.3	0
30	Recent advances in the electrochemical sensing of lung cancer biomarkers. Biosensors and Bioelectronics: X, 2022, 12, 100235.	0.9	1
31	Extremely Simple and Rapid HPLC Analysis of Tocilizumab in Human Serum with Selective Precipitation Using Alkylamine. Chemical and Pharmaceutical Bulletin, 2023, 71, 19-23.	0.6	1